

REMARKS

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page(s) is captioned "Version With Markings To Show Changes Made."

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:ecb
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS

3. A method according to claim 1 or claim 2 wherein the cells are plant cells.

5. A method according to any one of the preceding claims 1 wherein the toxin is a bacterial toxin of a post-segregational killing system.

6. A method according to any one of the preceding claims 1 wherein the toxin interferes with DNA replication, and thereby impedes cell cycle progression and/or triggers programmed cell death.

7. A method according to claim 5 or claim 6 wherein the toxin targets *DnaB*.

10. A method according to any one of the preceding claims 1 wherein said toxin is provided within said cells by means of nucleic acid encoding said toxin under control of appropriate control elements for expression.

12. A method according to any one of the preceding claims 1 or 11 comprising providing to said cells said toxin and an antidote to the toxin, wherein both toxin and antidote are proteins, and controlling activity of said antidote on said toxin to control activity of said toxin on said cells.

14. A method according to claim 12 or claim 13 wherein selectivity for expression said toxin within target cells is effected by a combination of (i) up-regulation of toxin production in target cells and (ii) down-regulation of toxin production in non-target cells and/or neutralisation of toxin activity in non-target cells.

16. A method according to ~~any one of~~ claims 12 to 15 wherein said target cells are tumour cells.

17. A method according to ~~any one~~ claims 11 to 16 wherein said toxin is *ParD* kid protein and said antidote is *ParD* kis protein.

18. A composition comprising:
(i) a bacterial toxin and an inhibitor of said toxin, optionally an antidote to said toxin wherein both toxin and antidote are proteins, or
(ii) nucleic acid encoding a bacterial toxin and an inhibitor of said toxin, optionally an antidote to said toxin wherein both toxin and antidote are proteins, for use in a therapeutic method according to ~~any one of~~ claims 4 or 11 to 17.